Bone-Induced Her2 Promotes Secondary Metastasis in HR⁺/Her2^– Breast Cancer

Scientists evaluated the prediction power of Her2-expressing circulating tumor cells (CTCs) after analyzing over 13,000 CTCs from a cohort of 137 metastatic breast cancer patients with initial HR+/Her2– status.